{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:20:14Z","timestamp":1784262014243,"version":"3.55.0"},"reference-count":19,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:00:00Z","timestamp":1565654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100011420","name":"SmithKline Beecham Pharma","doi-asserted-by":"publisher","award":["NCT02829320"],"award-info":[{"award-number":["NCT02829320"]}],"id":[{"id":"10.13039\/100011420","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Ther Apher Dial"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Daprodustat is an oral hypoxia\u2010inducible factor prolyl hydroxylase inhibitor developed for treating anemia of chronic kidney disease. This 24\u2010week, phase 3, open\u2010label study (NCT02829320) evaluated whether daprodustat could achieve and maintain target hemoglobin levels in Japanese hemodialysis patients with anemia not receiving an erythropoiesis\u2010stimulating agent. Twenty\u2010eight patients received daprodustat 4\u2009mg once daily for 4\u2009weeks, after which doses were adjusted to achieve a hemoglobin target of 10.0 to 12.0\u2009g\/dL (inclusive). Baseline mean hemoglobin was 9.10\u2009g\/dL and mean change from baseline at 4\u2009weeks was 0.79\u2009g\/dL (95% CI, 0.53 to 1.05). Mean hemoglobin levels reached the target range by week 8 and were maintained within this range through week 24. Daprodustat 4\u2009mg once daily increased hemoglobin over the first 4\u2009weeks. Throughout the 24\u2010week study, daprodustat achieved and maintained hemoglobin within the target range and no new safety concerns were identified in hemodialysis patients not receiving erythropoiesis\u2010stimulating agents.<\/jats:p>","DOI":"10.1111\/1744-9987.12962","type":"journal-article","created":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T17:13:33Z","timestamp":1563210813000},"page":"108-114","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["A 24\u2010Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients"],"prefix":"10.1111","volume":"24","author":[{"given":"Yoshiharu","family":"Tsubakihara","sequence":"first","affiliation":[{"name":"Graduate School of Health Care Sciences, Jikei Institute  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Akizawa","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine Showa University  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology The University of Tokyo Graduate School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Onoue","sequence":"additional","affiliation":[{"name":"Biomedical Data Sciences, Japan Development, GlaxoSmithKline  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeko","family":"Yonekawa","sequence":"additional","affiliation":[{"name":"Medicines Development, Japan Development, GlaxoSmithKline  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9921-090X","authenticated-orcid":false,"given":"Hideki","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Medicines Development, Japan Development, GlaxoSmithKline  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Endo","sequence":"additional","affiliation":[{"name":"Medicines Development, Japan Development, GlaxoSmithKline  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Cobitz","sequence":"additional","affiliation":[{"name":"Future Pipelines Development, GlaxoSmithKline  Collegeville PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,8,13]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2017.09.026"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2011111078"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907845"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065485"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.295"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1005109"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfn601"},{"key":"e_1_2_6_9_1","volume-title":"US Food and Drug Administration","year":"2011"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.481"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41100-017-0114-y"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12712"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.11.021"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014111139"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015091009"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfy013"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfy014"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000454818"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2010.00836.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.05-1494"}],"container-title":["Therapeutic Apheresis and Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1744-9987.12962","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1744-9987.12962","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1744-9987.12962","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T01:33:45Z","timestamp":1694050425000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1744-9987.12962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,13]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1111\/1744-9987.12962"],"URL":"https:\/\/doi.org\/10.1111\/1744-9987.12962","archive":["Portico"],"relation":{},"ISSN":["1744-9979","1744-9987"],"issn-type":[{"value":"1744-9979","type":"print"},{"value":"1744-9987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,13]]},"assertion":[{"value":"2019-04-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}